Theravance Biopharma
TBPH
TBPH
168 hedge funds and large institutions have $927M invested in Theravance Biopharma in 2025 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 71 increasing their positions, 47 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
4% more funds holding
Funds holding: 161 → 168 (+7)
1.81% more ownership
Funds ownership: 96.06% → 97.87% (+1.8%)
Holders
168
Holding in Top 10
5
Calls
$2.55M
Puts
$16K
Top Buyers
| 1 | +$5.62M | |
| 2 | +$5.08M | |
| 3 | +$4.53M | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.35M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$3.92M |
Top Sellers
| 1 | -$18.3M | |
| 2 | -$10.8M | |
| 3 | -$6.98M | |
| 4 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$6.5M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$3.05M |
